• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉内与动脉内对比剂在疑似冠状动脉疾病患者中的肾脏损伤:一项随机试验。

Kidney Injury after Intravenous versus Intra-arterial Contrast Agent in Patients Suspected of Having Coronary Artery Disease: A Randomized Trial.

机构信息

From the Department of Radiology, Charité-Universitätsmedizin Berlin, Humboldt-Universität and Freie Universität zu Berlin, Schumannstr 20/21, Berlin 10117, Germany (E.S., M.B., E.Z., R.T, M.L., M.D.); and Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany (P.M.).

出版信息

Radiology. 2019 Sep;292(3):664-672. doi: 10.1148/radiol.2019182220. Epub 2019 Jul 2.

DOI:10.1148/radiol.2019182220
PMID:31264950
Abstract

Background In the absence of randomized studies, it has been controversial whether the likelihood of acute kidney injury (AKI) differs between intravenous and intra-arterial contrast agent administration. Purpose To compare intravenous versus intra-arterial contrast agent administration in relationship to AKI and analyze the association between AKI and chronic kidney disease (defined as at least mildly decreased estimated glomerular filtration rates [eGFRs]). Materials and Methods This was a prospective study (: NCT00844220) that involved randomizing participants with atypical chest pain and suspected coronary artery disease (CAD) between February 2009 and August 2015 to undergo coronary CT angiography with intravenous contrast agent administration or cardiac catheterization angiography with intra-arterial contrast agent administration. This prespecified secondary analysis compared AKI (serum creatinine increase of ≥ 25% or 0.5 mg/dL after 18-24 or 46-50 hours) determined by blinded investigators using absolute differences and relative risks, including two-sided 95% confidence intervals (CIs). Results A total of 320 participants (163 [50.9%] women; mean age, 60 years ± 11) were included. Baseline eGFR did not differ between the CT angiography group (84.3 mL/min/1.73 m ± 17.2) and the catheterization group (87.1 mL/min/1.73 m ± 16.7) ( = .14). AKI occurred in nine of 161 participants in the CT angiography group (5.6%; 95% CI: 3%, 10%) and in 21 of 159 participants in the catheterization group (13.2%; 95% CI: 9%,19%) (relative risk, 2.4; 95% CI: 1.1, 5.0; = .02). Also in the subgroup of participants without obstructive CAD, in those not requiring coronary interventions, AKI was more common in the catheterization group (11.9%; 95% CI: 8%, 19%) than in the CT angiography group (4.3% [95% CI: 2%, 9%]; difference, 7.7% [95% CI: 1.3%, 14.1%]; relative risk, 2.8 [95% CI: 1.1, 7.0]; = .02). Obstructive CAD (odds ratio [OR]: 2.7 [95% CI: 1.1, 6.6]; = .02), femoral catheter access (OR: 2.5 [95% CI: 1.1, 5.6]; = .04), and cine ventriculography were associated with AKI (OR: 2.3 [95% CI: 1.0, 4.9]; = .03). In multivariable analysis, the presence of postcontrast AKI was associated with chronic kidney disease (hazard ratio: 12.4 [95% CI: 4.5, 34.6]; < .01). Conclusion Acute kidney injury was more common after cardiac catheterization than after CT angiography in this prospective randomized study of patients suspected of having coronary artery disease. © RSNA, 2019 See also the editorial by Einstein and Newhouse in this issue.

摘要

背景 在缺乏随机研究的情况下,静脉内和动脉内造影剂给药导致急性肾损伤 (AKI) 的可能性是否不同一直存在争议。

目的 比较静脉内与动脉内造影剂给药与 AKI 的关系,并分析 AKI 与慢性肾脏病 (定义为肾小球滤过率 [eGFR] 至少轻度下降) 之间的关系。

材料与方法 这是一项前瞻性研究(NCT00844220),纳入了 2009 年 2 月至 2015 年 8 月期间疑似患有非典型胸痛和冠心病 (CAD) 的参与者,将他们随机分配接受静脉内造影剂冠状动脉 CT 血管造影或经导管冠状动脉造影。本预设的次要分析比较了由盲法研究者使用绝对差值和相对风险(包括双侧 95%置信区间 [CI])确定的 AKI(血清肌酐增加≥25%或 18-24 或 46-50 小时后增加 0.5mg/dL)。

结果 共纳入 320 名参与者(163 名 [50.9%] 为女性;平均年龄 60 岁±11 岁)。CT 血管造影组(84.3 mL/min/1.73 m±17.2)和导管组(87.1 mL/min/1.73 m±16.7)的基线 eGFR 无差异( =.14)。CT 血管造影组有 9 名(5.6%)参与者和导管组有 21 名(13.2%)参与者发生 AKI(相对风险,2.4;95%CI:1.1,5.0; =.02)。在没有阻塞性 CAD 的亚组中,在不需要冠状动脉介入治疗的患者中,导管组 AKI 更常见(11.9%;95%CI:8%,19%),而 CT 血管造影组(4.3% [95%CI:2%,9%];差异,7.7% [95%CI:1.3%,14.1%];相对风险,2.8 [95%CI:1.1,7.0]; =.02)。阻塞性 CAD(比值比 [OR]:2.7 [95%CI:1.1, 6.6]; =.02)、股动脉入路(OR:2.5 [95%CI:1.1, 5.6]; =.04)和电影心室造影与 AKI 相关(OR:2.3 [95%CI:1.0, 4.9]; =.03)。多变量分析显示,造影后 AKI 与慢性肾脏病有关(风险比:12.4 [95%CI:4.5, 34.6]; <.01)。

结论 在这项对疑似患有 CAD 的患者进行的前瞻性随机研究中,与 CT 血管造影相比,经导管冠状动脉造影后 AKI 更常见。

©RSNA,2019 也可参见本期 Einstein 和 Newhouse 的社论。

相似文献

1
Kidney Injury after Intravenous versus Intra-arterial Contrast Agent in Patients Suspected of Having Coronary Artery Disease: A Randomized Trial.静脉内与动脉内对比剂在疑似冠状动脉疾病患者中的肾脏损伤:一项随机试验。
Radiology. 2019 Sep;292(3):664-672. doi: 10.1148/radiol.2019182220. Epub 2019 Jul 2.
2
Radial access protects from contrast media induced nephropathy after cardiac catheterization procedures.径向入路可预防心导管检查术后对比剂诱导的肾病。
Clin Res Cardiol. 2018 Feb;107(2):148-157. doi: 10.1007/s00392-017-1166-2. Epub 2017 Sep 22.
3
Acute Kidney Injury After Intravenous Versus Intra-Arterial Contrast Material Administration in a Paired Cohort.配对队列中静脉注射与动脉注射造影剂后的急性肾损伤
Invest Radiol. 2016 Dec;51(12):804-809. doi: 10.1097/RLI.0000000000000298.
4
Effect of a Contrast Modulation System on Contrast Media Use and the Rate of Acute Kidney Injury After Coronary Angiography.对比调制系统对冠状动脉造影后对比剂使用和急性肾损伤发生率的影响。
JACC Cardiovasc Interv. 2018 Aug 27;11(16):1601-1610. doi: 10.1016/j.jcin.2018.04.007.
5
Risk of Acute Kidney Injury Following Contrast-enhanced CT in Hospitalized Pediatric Patients: A Propensity Score Analysis.住院儿科患者行增强 CT 检查后发生急性肾损伤的风险:倾向评分分析。
Radiology. 2020 Mar;294(3):548-556. doi: 10.1148/radiol.2020191931. Epub 2020 Jan 21.
6
Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.N-乙酰半胱氨酸或抗坏血酸与安慰剂相比在接受择期心导管插入术患者中预防造影剂诱发急性肾损伤的有效性:一项单中心、前瞻性、随机、双盲、安慰剂对照试验
J Invasive Cardiol. 2013 Jun;25(6):276-83.
7
Contrast-induced acute kidney injury and clinical outcomes after intra-arterial and intravenous contrast administration: risk comparison adjusted for patient characteristics by design.对比剂诱导的急性肾损伤与经动脉和静脉内应用对比剂后的临床结局:通过设计调整患者特征后的风险比较。
Am Heart J. 2013 May;165(5):793-99, 799.e1. doi: 10.1016/j.ahj.2013.02.013. Epub 2013 Mar 27.
8
Intravenous CT Contrast Media and Acute Kidney Injury: A Multicenter Emergency Department-based Study.静脉注射 CT 对比剂与急性肾损伤:一项基于多中心急诊科的研究。
Radiology. 2021 Dec;301(3):571-581. doi: 10.1148/radiol.2021204446. Epub 2021 Oct 12.
9
Is Intravenous Administration of Iodixanol Associated with Increased Risk of Acute Kidney Injury, Dialysis, or Mortality? A Propensity Score-adjusted Study.碘克沙醇静脉给药是否会增加急性肾损伤、透析或死亡率的风险?一项倾向评分调整研究。
Radiology. 2017 Nov;285(2):414-424. doi: 10.1148/radiol.2017161573. Epub 2017 Jul 13.
10
Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.肾素-血管紧张素阻滞剂撤药与继续用药对接受心脏导管插入术的肾功能不全患者急性肾损伤发生率的影响:心脏导管插入术患者中血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂与对比剂诱导的肾病(CAPTAIN)试验结果
Am Heart J. 2015 Jul;170(1):110-6. doi: 10.1016/j.ahj.2015.04.019. Epub 2015 Apr 18.

引用本文的文献

1
Contrast-induced acute kidney injury and nephrogenic systemic fibrosis in children.儿童对比剂诱导的急性肾损伤和肾源性系统性纤维化
Pediatr Nephrol. 2025 Aug 11. doi: 10.1007/s00467-025-06916-w.
2
Risk-Stratified Prognostic Implications of Contrast-Associated Acute Kidney Injury After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后对比剂相关急性肾损伤的风险分层预后意义
JACC Adv. 2025 Jul;4(7):101899. doi: 10.1016/j.jacadv.2025.101899.
3
Cardiac Evaluation in Liver Transplant Candidates.肝移植候选者的心脏评估
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102554. doi: 10.1016/j.jceh.2025.102554. Epub 2025 Mar 27.
4
LTSI Consensus Guidelines: Preoperative Cardiac Evaluation in Adult Liver Transplant Recipients.LTSI 共识指南:成人肝移植受者的术前心脏评估
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102419. doi: 10.1016/j.jceh.2024.102419. Epub 2024 Oct 18.
5
Use of questionnaires in outpatients at low-risk for post-contrast acute kidney injury scheduled for intravenous iodine-based contrast media administration: a proposal for computed tomography coronary angiography.将接受静脉注射碘造影剂的造影剂后急性肾损伤低风险门诊患者问卷的使用:计算机断层扫描冠状动脉造影的建议
Quant Imaging Med Surg. 2024 Dec 5;14(12):9712-9719. doi: 10.21037/qims-24-968. Epub 2024 Sep 18.
6
Current updates in radiocontrast-associated acute kidney injury.放射性对比剂相关急性肾损伤的最新进展
Proc (Bayl Univ Med Cent). 2024 Aug 29;37(6):938-944. doi: 10.1080/08998280.2024.2395765. eCollection 2024.
7
Evaluation of the Diagnostic Utility of Urine Biomarkers Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) and Insulin-like Growth Factor Binding Protein-7 (IGFBP-7) in Predicting Acute Kidney Injury and Short-term Outcomes among High-risk, Critically Ill Patients in a Tertiary Government Hospital in the Philippines.菲律宾一家三级政府医院中,评估尿生物标志物金属蛋白酶组织抑制剂-2(TIMP-2)和胰岛素样生长因子结合蛋白-7(IGFBP-7)在预测高危重症患者急性肾损伤及短期预后方面的诊断效用。
Acta Med Philipp. 2024 Sep 13;58(16):14-22. doi: 10.47895/amp.v58i16.7066. eCollection 2024.
8
Efficacy of Chronic Use of Sodium-Glucose Co-transporter 2 Inhibitors on the Prevention of Contrast-Induced Acute Kidney Injury in Patients with Type 2 Diabetes Mellitus Following Coronary Procedures: A Systematic Review and Meta-Analysis.2型糖尿病患者冠状动脉手术后长期使用钠-葡萄糖协同转运蛋白2抑制剂预防造影剂诱导的急性肾损伤的疗效:一项系统评价和荟萃分析
Am J Cardiovasc Drugs. 2025 Jan;25(1):57-69. doi: 10.1007/s40256-024-00684-y. Epub 2024 Oct 11.
9
Novel Insights into Diabetic Kidney Disease.糖尿病肾病的新见解。
Int J Mol Sci. 2024 Sep 23;25(18):10222. doi: 10.3390/ijms251810222.
10
ESR Essentials: imaging in stable chest pain - practice recommendations by ESCR.ESR 精华:稳定型胸痛的影像学检查——ESCR 的实践建议。
Eur Radiol. 2024 Oct;34(10):6559-6567. doi: 10.1007/s00330-024-10739-y. Epub 2024 Apr 16.